Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.

Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, Lievens Y, de Jong MC, Bussink J, Geets X, Valentini V, Elia G, Neri D, Billiet C, Abdollahi A, Pasquier D, Boisselier P, Yaromina A, De Ruysscher D, Dubois LJ, Lambin P

Open source

DOI: 10.1186/s12885-020-07055-1
Published: 2020 Jun 15
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-020-07055-1,
  title = {Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.},
  author = {Lieverse RIY and Van Limbergen EJ and Oberije CJG and Troost EGC and Hadrup SR and Dingemans AC and Hendriks LEL and Eckert F and Hiley C and Dooms C and Lievens Y and de Jong MC and Bussink J and Geets X and Valentini V and Elia G and Neri D and Billiet C and Abdollahi A and Pasquier D and Boisselier P and Yaromina A and De Ruysscher D and Dubois LJ and Lambin P},
  year = {2020},
  journal = {BMC cancer},
  doi = {10.1186/s12885-020-07055-1},
  url = {https://doi.org/10.1186/s12885-020-07055-1}
}

RIS

TY  - JOUR
TI  - Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
AU  - Lieverse RIY
AU  - Van Limbergen EJ
AU  - Oberije CJG
AU  - Troost EGC
AU  - Hadrup SR
AU  - Dingemans AC
AU  - Hendriks LEL
AU  - Eckert F
AU  - Hiley C
AU  - Dooms C
AU  - Lievens Y
AU  - de Jong MC
AU  - Bussink J
AU  - Geets X
AU  - Valentini V
AU  - Elia G
AU  - Neri D
AU  - Billiet C
AU  - Abdollahi A
AU  - Pasquier D
AU  - Boisselier P
AU  - Yaromina A
AU  - De Ruysscher D
AU  - Dubois LJ
AU  - Lambin P
PY  - 2020
JO  - BMC cancer
DO  - 10.1186/s12885-020-07055-1
UR  - https://doi.org/10.1186/s12885-020-07055-1
ER  -

APA

RIY, L., EJ, V. L., CJG, O., EGC, T., SR, H., AC, D., LEL, H., F, E., C, H., C, D., Y, L., MC, D. J., J, B., X, G., V, V., G, E., D, N., C, B., A, A., D, P., P, B., A, Y., D, D. R., LJ, D., & P, L. (2020). Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.. BMC cancer. https://doi.org/10.1186/s12885-020-07055-1

Source records

pubmed · retrieved 2026-09-26T05:08:19.685Z